IGMS and MVIRB Related Headlines
Go Back- Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA
- Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC
- Medivir's patent application for fostrox approved in China
- Medivir to present at the Redeye Growth Day
- Change in the number of shares and votes in Medivir AB (publ)
- Medivir to present at the ABGSC Life Science Summit
- Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023
- Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)
- Resolutions at the Annual General Meeting in Medivir on 4 May 2023
IGMS and MVIRB Related Press Releases
Go Back- Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA
- Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC
- Medivir's patent application for fostrox approved in China
- Medivir to present at the Redeye Growth Day
- Change in the number of shares and votes in Medivir AB (publ)
- Medivir to present at the ABGSC Life Science Summit
- Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023
- Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)
- Resolutions at the Annual General Meeting in Medivir on 4 May 2023
